MX2009012772A - Nuevo derivado de amida para inhibir el crecimiento de celulas cancerosas. - Google Patents

Nuevo derivado de amida para inhibir el crecimiento de celulas cancerosas.

Info

Publication number
MX2009012772A
MX2009012772A MX2009012772A MX2009012772A MX2009012772A MX 2009012772 A MX2009012772 A MX 2009012772A MX 2009012772 A MX2009012772 A MX 2009012772A MX 2009012772 A MX2009012772 A MX 2009012772A MX 2009012772 A MX2009012772 A MX 2009012772A
Authority
MX
Mexico
Prior art keywords
cancer cells
growth
amide derivative
inhibiting
novel amide
Prior art date
Application number
MX2009012772A
Other languages
English (en)
Inventor
Gwan Sun Lee
Mi Young Cha
Maeng Sup Kim
Han Kyong Kim
Se Young Kim
Kwang-Ok Lee
Mi Ra Kim
Young Hee Jung
Chan Gon Lee
Keukchan Bang
Bum Woo Park
Bo Im Choi
Yun Jung Chae
Mi Young Ko
Young-Gil Ahn
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2009012772A publication Critical patent/MX2009012772A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona un nuevo derivado de amida y una sal farmacéuticamente aceptable del mismo el cual inhibe selectiva y efectivamente el crecimiento de células cancerosas inducido por la sobre-expresión de un receptor del factor de crecimiento epidérmico y que también previene el desarrollo de resistencia al fármaco causado por la mutación de tirosina cinasa EGFR, y una composición farmacéutica que comprende lo mismo que un ingrediente activo.
MX2009012772A 2007-06-05 2008-06-05 Nuevo derivado de amida para inhibir el crecimiento de celulas cancerosas. MX2009012772A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070054997 2007-06-05
PCT/KR2008/003162 WO2008150118A2 (en) 2007-06-05 2008-06-05 Novel amide derivative for inhibiting the growth of cancer cells

Publications (1)

Publication Number Publication Date
MX2009012772A true MX2009012772A (es) 2009-12-15

Family

ID=40094307

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012772A MX2009012772A (es) 2007-06-05 2008-06-05 Nuevo derivado de amida para inhibir el crecimiento de celulas cancerosas.

Country Status (25)

Country Link
US (1) US8188102B2 (es)
EP (1) EP2167492B1 (es)
JP (1) JP5155391B2 (es)
KR (1) KR101013319B1 (es)
CN (1) CN101679384B (es)
AR (2) AR066876A1 (es)
AU (1) AU2008260772B2 (es)
BR (1) BRPI0811069B1 (es)
CA (1) CA2687180C (es)
DK (1) DK2167492T3 (es)
ES (1) ES2558623T3 (es)
HK (1) HK1142591A1 (es)
HR (1) HRP20160007T1 (es)
HU (1) HUE028243T2 (es)
IL (1) IL202154A (es)
MX (1) MX2009012772A (es)
MY (1) MY144972A (es)
NZ (1) NZ582412A (es)
PL (1) PL2167492T3 (es)
PT (1) PT2167492E (es)
RU (1) RU2434010C2 (es)
TW (1) TWI377944B (es)
UA (1) UA96045C2 (es)
WO (1) WO2008150118A2 (es)
ZA (1) ZA201000022B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
BRPI0715016A2 (pt) 2006-09-11 2013-05-28 Curis Inc composiÇço, composiÇço farmacÊutica, mÉtodo para tratar uma doenÇa ou distérbio relacionada com tirosina quinase de egfr em um individuo necessitando o mesmo, mÉtodo para tratar uma doenÇa mediada por hdac e mÉtodo para tratar doenÇas medidas tanto por tirosina quinase de egfr quanto hdac
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
KR101317809B1 (ko) * 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR101272613B1 (ko) * 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
CN110194748A (zh) 2012-01-13 2019-09-03 艾森生物科学公司 杂环化合物及其作为抗癌药的用途
US9085540B2 (en) 2012-01-17 2015-07-21 Astellas Pharma Inc. Pyrazinecarboxamide compound
CN102659764A (zh) * 2012-04-16 2012-09-12 中国科学院广州生物医药与健康研究院 酪氨酸激酶不可逆抑制剂及其制备方法和用途
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
ES2761572T3 (es) 2013-07-11 2020-05-20 Acea Therapeutics Inc Derivados de pirimidina como inhibidores de quinasa
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
WO2015154725A1 (zh) * 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
WO2016090174A1 (en) * 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
EP3272746B1 (en) * 2015-03-20 2019-12-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of quinazoline derivative and method for preparing same
RU2018115334A (ru) 2015-10-09 2019-11-11 Ацея Терапьютикс, Инк. Фармацевтические соли, физические формы и композиции пирролопиримидиновых ингибиторов киназ, и способы их получения
WO2018036539A1 (zh) * 2016-08-25 2018-03-01 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐的晶体
CN108069946B (zh) * 2016-11-08 2020-06-05 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的取代的喹唑啉化合物
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3590929B1 (en) 2017-02-28 2021-09-15 Medshine Discovery Inc. Spiro compound and use thereof
EP3606925A1 (en) 2017-04-07 2020-02-12 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
AU2018259078B2 (en) * 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
UY37935A (es) * 2017-10-18 2020-03-31 Spectrum Pharmaceuticals Inc Inhibidores de tirosina quinasas de la familia de los egfr mutantes
JP7296641B2 (ja) * 2017-12-19 2023-06-23 チェンドゥ・ジンルイ・ファウンデーション・バイオテック・カンパニー・リミテッド キナゾリン誘導体およびその使用
EA202091491A1 (ru) 2017-12-21 2020-11-13 Бёрингер Ингельхайм Интернациональ Гмбх Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
MX2020010121A (es) 2018-03-27 2021-01-08 Univ Texas Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano.
CN110054613B (zh) * 2018-05-24 2020-11-27 深圳市塔吉瑞生物医药有限公司 取代的氨基喹唑啉类化合物及其药物组合物及其用途
CN110577514B (zh) * 2018-06-08 2022-07-05 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
WO2019233459A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
CN108623490A (zh) * 2018-06-22 2018-10-09 苏州市贝克生物科技有限公司 (2z)-4-(二甲基氨基)-2-丁烯酸盐酸盐的合成方法
TW202019412A (zh) 2018-06-25 2020-06-01 美商光譜製藥公司 波齊替尼(poziotinib)與細胞毒性劑及／或其他分子靶向劑之組合及其用途
TW202012391A (zh) * 2018-07-04 2020-04-01 日商第一三共股份有限公司 二芳基醚型喹唑啉衍生物
US20220040180A1 (en) * 2018-09-14 2022-02-10 Spectrum Pharmaceuticals, Inc. Kits and methods for treating cancers
KR20210066841A (ko) * 2018-09-21 2021-06-07 스펙트럼 파마슈티컬즈 인크 신규한 퀴나졸린 egfr 억제제
MX2021003517A (es) 2018-09-25 2021-08-16 Black Diamond Therapeutics Inc Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
KR101950942B1 (ko) 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
JP7109013B2 (ja) 2019-03-19 2022-07-29 ボロノイ インコーポレイテッド ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
CA3137901A1 (en) * 2019-04-25 2020-10-29 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase
WO2020227711A1 (en) 2019-05-09 2020-11-12 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
JP7350374B2 (ja) * 2019-06-19 2023-09-26 チェンドゥ・ジンルイ・ファウンデーション・バイオテック・カンパニー・リミテッド キナゾリン系化合物の結晶体、塩およびその調製方法
WO2020262998A1 (ko) * 2019-06-26 2020-12-30 한미약품 주식회사 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물
KR20210049004A (ko) 2019-10-24 2021-05-04 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체를 포함하는 약제학적 제제 및 이를 포함하는 약제학적 제품
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
CA3166298A1 (en) * 2020-01-29 2021-08-05 John Heymach Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions
WO2021231400A1 (en) * 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors
CN111763215B (zh) * 2020-07-21 2021-05-18 成都海博为药业有限公司 一种具有含氮杂环结构的化合物及其制备方法和用途
WO2022105908A1 (zh) * 2020-11-23 2022-05-27 上海和誉生物医药科技有限公司 Egfr抑制剂及其制备方法与在药学上的应用
WO2022170043A1 (en) * 2021-02-05 2022-08-11 Accutar Biotechnology, Inc. Quinazoline derived compounds as egfr inhibitors and their uses thereof
TW202317126A (zh) 2021-06-15 2023-05-01 美商建南德克公司 Ｅｇｆｒ抑制劑和ｐｅｒｋ活化劑組合療法
WO2022266426A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof
WO2022266427A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 4-(aryl-methyl-amino)-quinazoline derivatives and uses thereof
AR126849A1 (es) * 2021-08-24 2023-11-22 Arthrosi Therapeutics Inc Compuestos de quinazolina para tratamiento de enfermedad
CN115894486B (zh) * 2021-09-30 2024-02-09 北京赛特明强医药科技有限公司 一种氢化吡啶并喹唑啉类化合物、组合物及其应用
WO2023128350A1 (ko) * 2021-12-30 2023-07-06 주식회사 비투에스바이오 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2024083120A1 (zh) * 2022-10-18 2024-04-25 南京明德新药研发有限公司 苄氨基喹啉类化合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
EA009300B1 (ru) 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
BRPI0413066A (pt) * 2003-07-29 2006-10-17 Astrazeneca Ab derivado de quinazolina, ou um sal farmaceuticamente aceitável, ou um éster farmaceuticamente aceitável do mesmo, da fórmula i, uso e processo para a preparação do mesmo, composto, composição farmacêutica, e, métodos para a produção de um efeito antiproliferativo em um animal de sangue quente, para a prevenção ou tratamento de um tumor, para prover um efeito inibitório de tirosina quinase de egfr seletivo, e para tratar um cáncer em um animal de sangue quente
WO2005026151A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
BRPI0414735A (pt) * 2003-09-25 2006-11-21 Astrazeneca Ab derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina
US7687502B2 (en) 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
CA2619037A1 (en) 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
WO2007055513A1 (en) * 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof

Also Published As

Publication number Publication date
KR20080107294A (ko) 2008-12-10
PL2167492T3 (pl) 2016-03-31
EP2167492B1 (en) 2015-10-14
WO2008150118A2 (en) 2008-12-11
ZA201000022B (en) 2011-04-28
AU2008260772A1 (en) 2008-12-11
CA2687180A1 (en) 2008-12-11
WO2008150118A3 (en) 2009-01-29
US20100179120A1 (en) 2010-07-15
NZ582412A (en) 2011-12-22
EP2167492A4 (en) 2010-12-15
PT2167492E (pt) 2016-02-04
KR101013319B1 (ko) 2011-02-09
JP5155391B2 (ja) 2013-03-06
MY144972A (en) 2011-11-30
ES2558623T3 (es) 2016-02-05
HRP20160007T1 (hr) 2016-02-12
RU2434010C2 (ru) 2011-11-20
AR110003A2 (es) 2019-02-13
HUE028243T2 (en) 2016-12-28
RU2009149307A (ru) 2011-07-20
IL202154A (en) 2014-05-28
JP2010529115A (ja) 2010-08-26
AR066876A1 (es) 2009-09-16
CN101679384A (zh) 2010-03-24
CA2687180C (en) 2012-07-24
CN101679384B (zh) 2013-10-16
BRPI0811069B1 (pt) 2022-08-30
AU2008260772B2 (en) 2011-06-02
BRPI0811069A2 (pt) 2014-12-09
EP2167492A2 (en) 2010-03-31
TW200906414A (en) 2009-02-16
DK2167492T3 (en) 2016-01-11
UA96045C2 (ru) 2011-09-26
IL202154A0 (en) 2010-06-16
US8188102B2 (en) 2012-05-29
TWI377944B (en) 2012-12-01
HK1142591A1 (en) 2010-12-10

Similar Documents

Publication Publication Date Title
MY144972A (en) Novel amide derivative for inhibiting the growth of cancer cells
WO2008060907A3 (en) Pyrrolo-pyridine kinase inhibitors
WO2011099764A3 (en) Novel pyrimidine derivative for inhibiting the growth of cancer cells
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MX2007007458A (es) Derivados de quinazolina para inhibir crecimiento de celulas cancerigenas y metodo para la preparacion de los mismos.
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
PH12015501483A1 (en) Heterocyclic compounds and uses thereof
UA99284C2 (ru) ИНГИБИТОРЫ р70 S6-КИНАЗЫ
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
PL2324008T3 (pl) 3,4-diarylopirazole jako inhibitory kinazy białkowej
WO2011093672A3 (en) Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
CY1113642T1 (el) Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
EP2476679A3 (en) Substituted triazoles useful as AXL inhibitors
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
TNSN08191A1 (en) Kinase inhibitors
DE602005023732D1 (de) Pyrrolotriazinverbindungen

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration
HC Change of company name or juridical status